TITLE

ENZO BIOCHEM TREATMENT RIDS TRANSPLANTATION SIDE EFFECTS

PUB. DATE
July 2000
SOURCE
Worldwide Biotech;Jul2000, Vol. 12 Issue 7, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the treatment developed by scientists at Hadassah University Hospital and Enzo Biochem Inc. which reversed the side effects of a graft versus host disease in an individual receiving bone marrow stem cell transplantation.
ACCESSION #
3350541

 

Related Articles

  • Ciclosporin.  // Reactions Weekly;6/7/2008, Issue 1205, p10 

    The article describes the case of a 37-year-old man who developed central pontine myelinolysis (CPM) with neurological deterioration, and subsequently died, following initiation of graft-versus-host disease (GVHD) prophylaxis after his haematopoietic stem cell transplantation (HSCT) for acute...

  • Osiris Targets GVHD With Stem Cell Therapy.  // Bioworld Week;10/22/2007, Vol. 15 Issue 43, p5 

    The article reports that Osiris Therapeutics Inc. is moving forward with a Phase III pivotal trial of its mesenchymal stem cell therapy Prochymal following the success of its Phase II trial in the U.S. The Prochymal is believed to be the first-line agent to treat acute graft-versus-host disease...

  • ARIAD'S GENE-TARGETED DRUG GRANTED ORPHAN DRUG STATUS.  // Biotech Business;Apr2000, Vol. 13 Issue 4, p2 

    Reports that ARIAD Pharmaceuticals Incorporated's gene-targeted drug has been granted an orphan drug status for the treatment of acute graft-versus-host disease by the Food and Drug Administration in April 2000.

  • Advances in the treatment of graft-versus-host disease. Vogelsang, G B // Leukemia (08876924);Mar2000, Vol. 14 Issue 3, p509 

    Graft-versus-host disease (GVHD) is a complicated disease whose treatment requires an equally multifaceted approach. Recipient conditioning, donor T cell activation, and end stage effectors all may be potential targets for treatment. Many drugs used in the past are returning to the forefront for...

  • Posaconazole Prophylaxis in Hematologic Cancer. Weiler, Stefan; Bellmann, Romuald // New England Journal of Medicine;5/24/2007, Vol. 356 Issue 21, p2214 

    This article presents a letter to the editor in response to "Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease," by A.J. Ullman et al. in the January 25, 2007 issue.

  • Posaconazole Prophylaxis in Hematologic Cancer. Kontoyiannis, Dimitrios P.; Lewis, Russell E. // New England Journal of Medicine;5/24/2007, Vol. 356 Issue 21, p2214 

    This article presents a letter to the editor in response to "Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease," by A.J. Ullman et al. in the January 25, 2007 issue.

  • Posaconazole Prophylaxis in Hematologic Cancer. Krause, David S. // New England Journal of Medicine;5/24/2007, Vol. 356 Issue 21, p2214 

    This article presents a letter to the editor in response to "Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease," by A.J. Ullman et al. in the January 25, 2007 issue.

  • Posaconazole Prophylaxis in Hematologic Cancer. van Nieuwkoop, Cees; van Dissel, Jaap T. // New England Journal of Medicine;5/24/2007, Vol. 356 Issue 21, p2214 

    This article presents a letter to the editor in response to "Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease," by A.J. Ullman et al. in the January 25, 2007 issue.

  • Posaconazole Prophylaxis in Hematologic Cancer. Ullmann, Andrew J.; Chandrasekar, Pranatharthi; Patino, Hernando // New England Journal of Medicine;5/24/2007, Vol. 356 Issue 21, p2214 

    This article presents a reply to letters to the editor in response to "Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease," by A.J. Ullman et al. in the January 25, 2007 issue.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics